Yoshihito Niki

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 732 citations

Antimicrobial Susceptibility, Health Sciences, Carbapenem-resistant Gram-negative Bacteria +11

A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

Shigeru Kohno, Toru Masaoka, Hideyo Yamaguchi et al. · Scandinavian Journal of Infectious Diseases · 2004 · 153 citations

Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan

Shigeru Kohno, Koichi Izumikawa, Kenji Ogawa et al. · Journal of Infection · 2010 · 130 citations · Full text

Antifungal Agent, Pharmacology, Medicinal Fungi +3

Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates

Yoshihiro Kobashi, Kouichiro Yoshida, Naoyuki Miyashita et al. · Journal of Infection and Chemotherapy · 2006 · 101 citations

Health Sciences, Respiratory Infection, Infectious Respiratory Disease +7

Chlamydia pneumoniae and Exacerbations of Asthma in Adults

Naoyuki Miyashita, Yoshifumi Kubota, Masamitsu Nakajima et al. · Annals of Allergy Asthma & Immunology · 1998 · 96 citations · Full text

Asthma, Respiratory Diseases, Respiratory Infection +4